research use only
Cat.No.S6384
| Related Targets | JAK TGF-beta/Smad Wnt/beta-catenin ERK GSK-3 ROCK PKA Secretase STAT Casein Kinase |
|---|---|
| Other Hedgehog/Smoothened Inhibitors | SAG (Smoothened Agonist) Hydrochloride Purmorphamine Cyclopamine (11-Deoxojervine) GANT61 SANT-1 HPI-4 (Ciliobrevin A) BMS-833923 Taladegib (LY2940680) Ciliobrevin D Jervine |
|
In vitro |
DMSO
: 98 mg/mL
(199.97 mM)
Ethanol : 98 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 490.06 | Formula | C28H28ClN3OS |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 912545-86-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CNC1CCC(CC1)N(CC2=CC(=CC=C2)C3=CC=NC=C3)C(=O)C4=C(Cl)C5=CC=CC=C5S4 | ||
| Targets/IC50/Ki |
Smo
(in Shh-LIGHT2 cells) 3 nM(EC50)
|
|---|---|
| In vitro |
Smoothened Agonist (SAG) can counteract glucocorticoids (GCs) antagonism of Shh-driven granule neuron precursor (CGNP) proliferation. |
| In vivo |
Systemic administration of Smoothened Agonist (SAG) prevents the neurotoxic effects of glucocorticoids. This compound can cross the blood-brain barrier to activate Shh transcriptional targets in vivo. At the treatment dose, it effectively prevents GC-induced neonatal cerebellar developmental abnormalities. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05937178 | Recruiting | Hepatitis B Chronic |
Huashan Hospital|The First Affiliated Hospital of Anhui Medical University|Anhui Provincial Hospital|Beijing YouAn Hospital|Peking University People''s Hospital|Peking University First Hospital|Xiamen Hospital of Traditional Chinese Medicine|First Affiliated Hospital of Fujian Medical University|LanZhou University|Third Affiliated Hospital Sun Yat-Sen University|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Hainan General Hospital|Hebei Medical University Third Hospital|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine|Henan Provincial People''s Hospital|The Second Affiliated Hospital of Harbin Medical University|Tongji Hospital|Wuhan Union Hospital China|Renmin Hospital of Wuhan University|Central South University|Xiangya Hospital of Central South University|The First Hospital of Jilin University|the Second Hospital of Nangjing|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|The First Affiliated Hospital with Nanjing Medical University|The Affiliated Hospital of Xuzhou Medical University|The First Affiliated Hospital of Nanchang University|Shengjing Hospital|Qingdao Sixth People''s Hospital|Shandong Provincial Hospital|The Second Hospital of Shandong University|The First Affiliated Hospital of Shanxi Medical University|Tang-Du Hospital|First Affiliated Hospital Xi''an Jiaotong University|Ruijin Hospital|West China Hospital|Tianjin Second People''s Hospital|First Affiliated Hospital of Xinjiang Medical University|The First People''s Hospital of Yunnan|Shulan (Hangzhou) Hospital|Zhejiang University|Southwest Hospital China|The Second Affiliated Hospital of Chongqing Medical University|Sichuan Provincial People''s Hospital |
January 31 2023 | -- |
| NCT05701592 | Recruiting | Posterior Cruciate Ligament Tear |
Konrad Malinowski MD|Artromedical Konrad Malinowski Clinic |
December 20 2022 | -- |
| NCT03645044 | Active not recruiting | Hiv|HBV Coinfection |
University of Melbourne|National Health and Medical Research Council Australia|The University of Western Australia|University of Adelaide|The HIV Netherlands Australia Thailand Research Collaboration|University of Malaya|YR Gaitonde Centre for AIDS Research and Education|Melbourne Health |
May 24 2018 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.